Purpose: To provide consensus-based current guidelines on optimal dosimetry and patient selection for MicroPulse Transscleral Laser Therapy (TLT) based on a review of the literature and a Delphi method.

Methods: A comprehensive search of Pub Med led to the identification and analysis of 61 studies on MicroPulse TLT that contained information on laser settings and patient selection. To determine consensus in areas where there was not enough available literature, a three-round Delphi method was conducted.

Results: The response rate was 90% in the first round, 90% in the second round, and 80% in the third round of the Delphi technique. Once all responses were aggregated, a live meeting was held with 80% attendance, and consensus was achieved on each of the findings detailed in this manuscript.

Conclusion: Micropulse TLT is a useful addition to the glaucoma armamentarium. When used with proper surgical technique at energy settings within the boundaries described in this manuscript, MicroPulse TLT is a safe and effective treatment for many types and stages of glaucoma. Based on current knowledge and experience, the consensus recommendation of this expert panel is that the standard MicroPulse TLT settings using the revised MicroPulse P3 Probe should be 2500 mW, 31.3% duty cycle, and 4 sweeps at a sweep velocity of 20 seconds each per hemisphere. Both hemispheres avoiding the 3 and 9 clock hours should be treated. The panel also reached consensus on patient selection for MicroPulse TLT providing guidance for the use of the procedure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188391PMC
http://dx.doi.org/10.2147/OPTH.S365647DOI Listing

Publication Analysis

Top Keywords

micropulse tlt
20
patient selection
16
micropulse
8
micropulse transscleral
8
transscleral laser
8
laser therapy
8
dosimetry patient
8
selection micropulse
8
tlt
6
evidence-based consensus
4

Similar Publications

Purpose: To investigate the clinical outcomes of micropulse transscleral laser therapy (MP-TLT) in a cohort of glaucoma patients, including safety profile, post-operative transient intraocular pressure (IOP) spikes, long-term efficacy and prognostic factors in terms of IOP-lowering.

Methods: This was a retrospective observational cohort study. Medical records of all patients who consecutively underwent MP-TLT between May 2019 and February 2023 at a tertiary referral centre were scrutinised and relevant data were retrospectively analysed.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to examine how MicroPulse transscleral laser therapy (MP-TLT) affects the sclera in patients with refractory glaucoma using a specific imaging technique called anterior segment-optical coherence tomography (AS-OCT).
  • Researchers enrolled 42 patients, measuring changes in scleral structures and intraocular pressure (IOP) before and after six months of treatment, with success defined as at least a one-third reduction in IOP.
  • Results showed that although all patients experienced scleral changes, significant correlations were found between certain scleral measurements and IOP reduction, suggesting that MP-TLT may enhance fluid outflow in the eye and help lower IOP in successful cases.
View Article and Find Full Text PDF

Clinical Outcomes of MicroPulse Transscleral Laser Therapy with the Revised P3 Delivery Device.

J Curr Glaucoma Pract

January 2024

Department of Medicine, Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States of America.

Aim: To evaluate the success and safety of MicroPulse transscleral laser therapy (TLT) on intraocular pressure (IOP) reduction in adults with uncontrolled glaucoma using different total treatment durations, sweep velocities, and a number of sweeps utilizing the revised MicroPulse P3 delivery device.

Materials And Methods: A single-center Institutional Review Board (IRB) approved multiple cohort studies of MicroPulse TLT with the revised MicroPulse P3 delivery device, which was conducted in 61 eyes from 40 adults with uncontrolled glaucoma. Eyes that received 50-second (GI, GII, and GIII) and 60-second (GIV, GV, and GVI) treatment applications between May and October 2020 were reviewed.

View Article and Find Full Text PDF

Outcomes of microPulse transscleral laser therapy in eyes with prior glaucoma aqueous tube shunt.

Graefes Arch Clin Exp Ophthalmol

October 2023

Doheny Eye Institute and Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, 625 S Fair Oaks Ave Suite 285, Pasadena, CA, 91105, USA.

Purpose: To evaluate the outcomes of micropulse transscleral laser therapy (MP-TLT) in patients with uncontrolled glaucoma and prior glaucoma aqueous tube shunt.

Methods: In this single‑center, retrospective, interventional case series, eyes that underwent MP-TLT and had prior glaucoma aqueous tube shunt surgeries were included. The Cyclo Glaucoma Laser System (IRIDEX Corporation, Mountain View, CA, USA) with the MicroPulse P3 probe (version 1) was used.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!